Syntara Reports Strong Clinical Progress in Blood Cancer Program
Syntara (ASX:SNT) is advancing multiple Phase 2 studies with its lead drug amsulostat, showing promising results in myelofibrosis, a rare and fatal bone marrow cancer.
According to CEO Gary Phillips,
73% of patients achieved a 50%+ reduction in symptoms and 44% saw major spleen volume reduction, with the drug also proving exceptionally safe and well-tolerated.
The information provided by Sequoia Financial Media is general in nature and not financial or investment advice. Viewers should obtain independent advice based on their own circumstances before making any financial decisions.
Author's summary: Syntara advances blood cancer program with promising results.
More News
- Employees are receiving renewed furlough notices as shutdown enters second month, this time without back pay guarantees
- No Giannis, No Problem — Bucks Take Down Warriors as Antetokounmpo Steals the Show in Minion Costume
- 0-12? Stephen Curry Drops Truth Bomb On Steve Kerr's Declaration After Losing To Bucks Without Giannis
- Can the United States Immediately Return to Nuclear Testing?
- Patriots' Rhamondre Stevenson is out for Sunday's game vs Falcons
- Donal Skehan takes cheeky dig at Eurosong controversy with perfect Halloween costume
- Why Ryan Rollins loved Draymond Green coming for him after Stephen Curry incident
- Bam Adebayo's evolution into 'three-level scorer' starts with Heat's new offense
- Gradam RTÉ Raidió na Gaeltachta 2025 to be presented to Mayo native - news - Western People
- Bose headphones and earbuds return to all-time lows for Black Friday